We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Novavax (NVAX - Free Report) ended the recent trading session at $8.68, demonstrating a -2.2% change from the preceding day's closing price. This change lagged the S&P 500's 0.55% loss on the day. At the same time, the Dow lost 0.19%, and the tech-heavy Nasdaq lost 0.95%.
Coming into today, shares of the vaccine maker had gained 17.95% in the past month. In that same time, the Medical sector lost 0.2%, while the S&P 500 gained 3.64%.
Market participants will be closely following the financial results of Novavax in its upcoming release. In that report, analysts expect Novavax to post earnings of -$0.26 per share. This would mark year-over-year growth of 65.79%. Alongside, our most recent consensus estimate is anticipating revenue of $67 million, indicating a 20.72% downward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.68 per share and revenue of $1.03 billion, which would represent changes of +317.89% and +51.52%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Novavax. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.75% upward. Novavax is holding a Zacks Rank of #3 (Hold) right now.
From a valuation perspective, Novavax is currently exchanging hands at a Forward P/E ratio of 3.31. This signifies a discount in comparison to the average Forward P/E of 19.47 for its industry.
It's also important to note that NVAX currently trades at a PEG ratio of 0.12. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.67.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 102, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Declines More Than Market: Some Information for Investors
Novavax (NVAX - Free Report) ended the recent trading session at $8.68, demonstrating a -2.2% change from the preceding day's closing price. This change lagged the S&P 500's 0.55% loss on the day. At the same time, the Dow lost 0.19%, and the tech-heavy Nasdaq lost 0.95%.
Coming into today, shares of the vaccine maker had gained 17.95% in the past month. In that same time, the Medical sector lost 0.2%, while the S&P 500 gained 3.64%.
Market participants will be closely following the financial results of Novavax in its upcoming release. In that report, analysts expect Novavax to post earnings of -$0.26 per share. This would mark year-over-year growth of 65.79%. Alongside, our most recent consensus estimate is anticipating revenue of $67 million, indicating a 20.72% downward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.68 per share and revenue of $1.03 billion, which would represent changes of +317.89% and +51.52%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Novavax. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.75% upward. Novavax is holding a Zacks Rank of #3 (Hold) right now.
From a valuation perspective, Novavax is currently exchanging hands at a Forward P/E ratio of 3.31. This signifies a discount in comparison to the average Forward P/E of 19.47 for its industry.
It's also important to note that NVAX currently trades at a PEG ratio of 0.12. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.67.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 102, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.